B+
Bull case
15%
Probability
Target price
$21.00
Analysis reference price unavailable
Analysis 2026-06-02 · RankAlpha Sentiment Codex
OCS
OculisDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The cash runway into 2H 2029 gives Oculis time to keep Privosegtor PIONEER and Licaminlimab PREDICT-1 alive; the DME miss is painful, but the retained retinal-thickness signal suggests the program still showed pharmacologic activity.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.8.
What can break
Any delay or weak data in the remaining programs could re-open financing and dilution questions despite the current runway.
Momentum
4
Value
41
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.00 · Bull $21.00 · Bear $5.00Analysis 2026-06-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $36.13
Why
Momentum4 · Δ7d -3.2
Value41 · Δ7d 0.0
Sentiment63 · Δ7d +5.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +5.8.
Contradictions & invalidation
- • Any delay or weak data in the remaining programs could re-open financing and dilution questions despite the current runway.
- • Low coverage and missing analyst revision data make sentiment and valuation unusually headline-driven.
- • OCS-01 missed the primary and key secondary efficacy endpoints, and management said it will not pursue an FDA filing in DME; the stock now depends on other late-stage assets to justify the remaining equity value.
Catalyst clock
2026-05-29
DIAMOND Phase 3 missed the primary DME vision endpoint
Lead driver: Sentiment · See AI snapshot
Momentum
4
9% active weight
Current posture
7d trendSoftening
Δ7d
-3.2
Δ21d
-0.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
63
62% active weight
Current posture
7d trendImproving
Δ7d
+5.8
Δ21d
+11.5
Why this grade
Composite grade D. Momentum 3.8 / Value 41.2 / Sentiment 62.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-02. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-06-02 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-06-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$751.21M
Beta
0.14
Shares Out
57.17M
P/E (TTM) · Derived
-5.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-9.10
Rev YoY
-
EPS YoY
-64.9%
Gross Margin
-
Op Margin
-
Net Debt
-$265.95M
Current Ratio
8.35
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data